Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neosaldina + placebo refers to the use of the fixed-dose combination drug Neosaldina administered alongside a placebo, typically in a clinical trial context. Neosaldina is a pharmaceutical product widely used in Brazil and other countries for the symptomatic treatment of headaches, migraines, and other pain conditions. It contains three active ingredients: - Metamizole sodium (also known as dipyrone), an analgesic and antipyretic with spasmolytic properties that acts primarily by inhibiting prostaglandin synthesis in the central nervous system. - Isometheptene mucate, a sympathomimetic agent that causes vasoconstriction of cerebral blood vessels and has mild analgesic and antispasmodic effects. - Caffeine, a central nervous system stimulant with vasoconstrictive action on cranial arteries. The "placebo" component is an inert substance used as a control in clinical trials to assess the efficacy or safety of Neosaldina. The combination "Neosaldina + placebo" does not represent a marketed pharmaceutical product but rather describes an intervention arm (active drug plus control) commonly found in randomized controlled trials evaluating headache treatments[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neosaldina + placebo.